文献速递肺栓塞与肺血管病呼吸道感染

COVID-19住院患者静脉血栓栓塞症与出血发生率:系统评价与Meta分析

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2020-11-17

该系统评价与Meta分析检索2020年1月1日至7月31日共15个标准来源及COVID-19专项来源,无语言限制,合并估计住院COVID-19患者VTE发生率为17.0%(95%CI 13.4-20.9),出血为7.8%(95%CI 2.6-15.3),大出血为3.9%(95%CI 1.2-7.9)。

要点

  • 住院COVID-19患者VTE合并发生率为17.0%,其中PE为7.1%。
  • ICU患者VTE发生率27.9%,高于病房患者的7.1%。
  • 筛查发现的VTE发生率33.1%,高于临床诊断的9.8%。

核心结论

  • 住院COVID-19患者VTE总体合并发生率为17.0%,出血事件发生率为7.8%。

研究设计与样本

  • 系统评价与Meta分析,检索2020年1月1日至7月31日共15个标准来源及COVID-19专项来源,无语言限制。
  • 采用随机效应模型合并发生率,用I2统计量评估异质性,用Begg和Egger检验评估发表偏倚。

主要发现

  • VTE合并发生率为17.0%(95%CI 13.4-20.9),DVT为12.1%(95%CI 8.4-16.4),PE为7.1%(95%CI 5.3-9.1)。
  • 出血合并发生率为7.8%(95%CI 2.6-15.3),大出血为3.9%(95%CI 1.2-7.9)。
  • 按筛查评估的VTE发生率为33.1%,临床诊断为9.8%;ICU患者为27.9%,病房患者为7.1%。
  • 前瞻性研究VTE发生率为25.5%,回顾性研究为12.4%。
  • 接受中等或全剂量抗凝患者出血合并发生率最高为21.4%,唯一前瞻性评估出血事件的研究最低为2.7%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individual studies have reported widely variable rates for VTE and bleeding among hospitalized patients with coronavirus disease 2019 (COVID-19). RESEARCH QUESTION: What is the incidence of VTE and bleeding among hospitalized patients with COVID-19? METHODS: In this systematic review and meta-analysis, 15 standard sources and COVID-19-specific sources were searched between January 1, 2020, and July 31, 2020, with no restriction according to language. Incidence estimates were pooled by using random effects meta-analyses. Heterogeneity was evaluated by using the I2 statistic, and publication bias was assessed by using the Begg and Egger tests. RESULTS: The pooled incidence was 17.0% (95% CI, 13.4-20.9) for VTE, 12.1% (95% CI, 8.4-16.4) for DVT, 7.1% (95% CI, 5.3-9.1) for pulmonary embolism (PE), 7.8% (95% CI, 2.6-15.3) for bleeding, and 3.9% (95% CI, 1.2-7.9) for major bleeding. In subgroup meta-analyses, the incidence of VTE was higher when assessed according to screening (33.1% vs 9.8% by clinical diagnosis), among patients in the ICU (27.9% vs 7.1% in the ward), in prospective studies (25.5% vs 12.4% in retrospective studies), and with the inclusion of catheter-associated thrombosis/isolated distal DVTs and isolated subsegmental PEs. The highest pooled incidence estimate of bleeding was reported for patients receiving intermediate- or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%). INTERPRETATION: Among hospitalized patients with COVID-19, the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT, and subsegmental PE, in critically ill patients and in prospective studies. Bleeding events were observed in 7.8% of patients and were sensitive to use of escalated doses of anticoagulants and nature of data collection. Additional studies are required to ascertain the significance of various thrombotic events and to identify strategies to improve patient outcomes. TRIAL REGISTRY: PROSPERO; No.: CRD42020198864; URL: https://www.crd.york.ac.uk/prospero/.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Jiménez D, García-Sanchez A, Rali P, et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2020. PMID: 33217420. doi:10.1016/j.chest.2020.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。